Paolo M. Rossini is full-professor of Neurology. Previous director of several, large departments of neuroscience in Italy (Catholic University in Rome). He is author of more than 750 peer-review papers, with an H-Index on Scopus of 102. He was President of the International Federation of Clinical Neurophysiology and chairman of the European Joint Programming on Demographic Changes. He is the national coordinator of the Interceptor project as well as the Principal Investigator for Italy in a EU-Commission-funded project on the use of artificial intelligence for early Alzheimer’s Disease diagnosis (AI-MIND).
University of Barcelona
Dr. Mònica Mir graduated in chemistry in 1998, and in 2006, she obtained her doctorate in biotechnology. She carried out a postdoctoral in Max Planck Institute. In 2008, she joined the Institute of Bioengineering of Catalonia as senior researcher while teaching as an Associate Professor at the University of Barcelona.
University of Pennsylvania
Dr. Tifani Biro is a postdoctoral researcher and Clark Scholar at Moss Rehabilitation Research Institute and the University of Pennsylvania's Alzheimer's Disease Research Center. Her focus is translational research on neurodegeneration's impact on the language network in individuals with Alzheimer's Disease. Recognizing the gap between basic and applied research, especially in psycholinguistics, she aims to bridge this divide. Dr. Biro's cross disciplinary training highlights the potential insights from basic research that can enhance our understanding and treatment of speech disorders. Her goal is to incorporate valuable findings into clinical literature, closing the gap between research and practice
Dr Griffioen holds a PhD in the field of biochemistry (Free University, Amsterdam, The Netherlands) and has held research positions at the University of Vienna (Austria) and the University of Leuven (Belgium). Currently Gerard is CSO at reMYND (Belgium) where he manages a diverse CNS drug development pipeline with a focus on age-related neurodegenerative diseases up to clinical phase 2. Gerard has been awarded several research grants, has published original research papers and reviews in peer-reviewed journals and is inventor of patents in the areas of drug discovery and development.
Jacques P. Tremblay
Jacques P. Tremblay
Professor Jacques P. Tremblay has been working on the development of cell and gene therapies for hereditary diseases (mainly Duchenne muscular dystrophy and Friedreich’s ataxia) since 1987. He has published 305 articles in peer-reviewed journals. He is very committed to the clinical application of his research work, as indicated by the conduct, in collaboration with a group of clinicians, of a Phase I clinical trial on 9 Duchenne patients. This trial demonstrated that transplantation onto normal allogeneic myoblasts led to the presence of the normal gene in muscle fibers. He received the award for best researcher in Quebec and the award for best researcher in Canada presented by Muscular Dystrophy Canada for his work on DMD. The Royal College of Physicians and Surgeons of Canada and the Canadian Society for Clinical Investigation presented me with the Henry Friesen Award. He is currently using CRISPR/Prime editing technology to correct point mutations in the APP, DMD, RYR1 and NKX6-2 genes.